Aripiprazole in Pervasive Developmental Disorder Not Otherwise Specified and Asperger's Disorder: A 14-Week, Prospective, Open-Label Study
| Autor: | Kimberly A. Stigler, Arlene E. Kohn, Christopher J. McDougle, David J. Posey, Jonathan T. Diener, Craig A. Erickson, Lang Li |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
medicine.medical_specialty Adolescent Psychometrics Aripiprazole Pilot Projects Quinolones Irritability Severity of Illness Index behavioral disciplines and activities Piperazines Body Mass Index mental disorders Severity of illness medicine Humans Pharmacology (medical) Prospective Studies Asperger Syndrome Child Psychiatry Prospective cohort study Original Research Pervasive developmental disorder not otherwise specified Psychiatric Status Rating Scales medicine.disease Irritable Mood Prolactin Psychiatry and Mental health Tolerability Child Development Disorders Pervasive Asperger syndrome Child Preschool Pediatrics Perinatology and Child Health Asperger's disorder Female medicine.symptom Psychology Antipsychotic Agents Clinical psychology medicine.drug |
| Zdroj: | Journal of Child and Adolescent Psychopharmacology. 19:265-274 |
| ISSN: | 1557-8992 1044-5463 |
| DOI: | 10.1089/cap.2008.093 |
| Popis: | The aim of this study was to determine the effectiveness and tolerability of aripiprazole for irritability in pervasive developmental disorder not otherwise specified (PDD-NOS) and Asperger's disorder.This is a 14-week, prospective, open-label investigation of aripiprazole in 25 children and adolescents diagnosed with PDD-NOS or Asperger's disorder. Primary outcome measures included the Clinical Global Impressions-Improvement (CGI-I) scale and the Irritability subscale of the Aberrant Behavior Checklist (ABC-I).Twenty-five subjects, ages 5-17 years (mean 8.6 years) received a mean final aripiprazole dosage of 7.8 mg/day (range 2.5-15 mg/day). Full-scale intelligence quotient (IQ) scores ranged from 48 to 122 (mean 84). Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final CGI-I of 1 or 2 (very much or much improved) and a 25% or greater improvement on the ABC-I. The final mean CGI-I was 1.6 (por= 0.0001). ABC-I scores ranged from 18 to 43 (mean 29) at baseline, whereas scores at week 14 ranged from 0 to 27 (mean 8.1) (por= 0.001). Aripiprazole was well tolerated. Mild extrapyramidal symptoms (EPS) were reported in 9 subjects. Age- and sex-normed body mass index (BMI) increased from a mean value of 20.3 at baseline to 21.1 at end point (por= 0.04). Prolactin significantly decreased from a mean value of 9.3 at baseline to 2.9 at end point (por= 0.0001). No subject exited the study due to a drug-related adverse event.These preliminary data suggest that aripiprazole may be effective and well tolerated for severe irritability in pediatric patients with PDD-NOS or Asperger's disorder. Larger-scale placebo-controlled studies are needed to elucidate the efficacy and tolerability of aripiprazole in this understudied population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|